Because the prognosis of ERBB2+ GC is poor, clarifying the mechanisms of drug sensitivity of ERBB2+ GC will be of clinical significance in ERBB2-targeted therapy (Wang et al., 2017). This evidence concerns the gene ERBB2 and gastric cancer.